We reported the case of a 73-year-old man for whom a prostatic adenocarcinoma with synchronous bone metastases was diagnosed. Because his disease was progressing despite several lines of chemotherapy and hormonotherapy, he was screened with a 68 Ga-PSMA PET/CT for a possible 177 Lu-PSMA-617 therapy. The examination demonstrated an intense diffuse bone uptake related to the known bone involvement. It also showed an unexpected diffuse and intense lung uptake, secondary to an active polyangiitis granulomata. This intense lung uptake prohibits the radioligand therapy.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.